| |
| |
| Exchange: |
Over The Counter |
| Security
Type: |
Common |
| Shares
Out: |
5,670,000 |
| Market
Cap: |
970.14(K) |
| Last
Volume: |
38,510 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1711 - $0.1711 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Diffusion Pharmaceuticals is a clinical stage biotechnology company. Co. is developing its primary product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC). TSC is designed to selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in various indications, including stroke, oncology and cardiovascular disease. Co.'s oncology program targets TSC against treatment-resistant brain cancer. In addition to the TSC programs, Co. is exploring alternatives to capitalize upon its product candidate RES-529, a PI3K/Akt/mTOR pathway inhibitor for age-related macular degeneration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
36 |
36 |
36 |
36 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kalergis David G |
Chairman and CEO |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,069,216 |
1,069,216 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
248,032 |
248,032 |
|
- |
|
| Gainer John |
Chief Scientific Officer |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
I/I |
3,725,711 |
3,725,711 |
|
- |
|
| Giles Mark T |
Director |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
I/I |
6,340,415 |
6,296,346 |
|
- |
|
| Byrne Thomas S |
Director |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,391,867 |
1,391,867 |
|
- |
|
| Adams Robert W |
Director |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
I/I |
188,973 |
188,973 |
|
- |
|
| Adams Robert W |
Director |
• • – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
350,504 |
350,504 |
|
- |
|
| Barer Sol J |
Chairman of the Board |
• • • |
2014-06-06 |
4/A |
OE |
$2.00 |
$1,105,476 |
D/D |
552,738 |
1,011,072 |
|
- |
|
| Barer Sol J |
Chairman of the Board |
• • • |
2014-06-06 |
4 |
OE |
$2.00 |
$1,105,476 |
D/D |
552,738 |
46,386,071 |
|
- |
|
59 Records found
|
|
Page 3 of 3 |
|
|
